Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. - Wikidata - wikimedia - TriplyDB

Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

http://www.wikidata.org/entity/Q39705893

about

Aldara activates TLR7-independent immune defence Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection.HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment Effects of imiquimod and low-intensity laser (λ660 nm) in chemically induced oral carcinomas in hamster buccal pouch mucosa.Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20.The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.Roles of the immune system in skin cancer.Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines Genome-Wide Association Studies of Multiple Keratinocyte Cancers.In vitro immunomodulation of a whole blood IFN-γ release assay enhances T cell responses in subjects with latent tuberculosis infection.Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.Role of TLR2-dependent inflammation in metastatic progression.Current adjuvants and new perspectives in vaccine formulation.Sinecatechins (Polyphenon E) ointment for treatment of external genital warts and possible future indications.Modes of action of TLR7 agonists in cancer therapy.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas.A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.Toll-like receptors: role in dermatological disease.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Recurrent vulvovaginal candidiasis: successful suppression with imiquimod.Inoculation of QuantiFERON-TB tubes with skin microbiota causes false-positive results.Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells.TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

P2860

Q28286677-932555F0-902D-4C09-B698-5ADB9F84D01E Q30276126-4C48F27E-5E6C-47AA-A605-743655E40BFC Q30422102-E688DFA2-43C0-427C-8CFD-6D57C3429F70 Q33678336-FC7AD566-AF4A-4B66-9F78-EAE621B20CB6 Q33824247-552F67A0-5D20-4CA8-BE4D-79C6AB39BE98 Q34290170-F4F32600-45D5-4781-870E-BB503C632E5C Q34401302-FAB36579-A6EF-4363-8147-1F5F0988A81F Q34624683-BF373CAF-611A-403F-B5CE-0465869C38D8 Q34788763-4DBCFD33-4811-4CDD-BF1F-3C5E2C5E4C96 Q35079913-C0BCB1E6-D3C4-443C-8EC2-0E8CFC5ADC51 Q35151677-7FD1352C-5F91-4877-95A7-18A1483C4C15 Q35176439-C07CC883-1E11-436F-B70D-58D98E6DDF6B Q35403714-8D6DAB76-E02C-4766-B4CE-856C29A064D8 Q35906771-B66B3134-08D2-4520-A18A-8D3464C236B0 Q36218717-DA39A5B9-F589-47E9-8AA8-A8C615D1174D Q36247721-0637D434-45A3-458F-B9E8-72CE48E72E5E Q36353973-E2CE7F61-E551-4E11-94C7-1B25D70D87AE Q36471507-C4F483A0-C57B-4538-A4AB-6C254571D164 Q36476394-497652CD-C826-4FA0-BCA9-31C7616A30E7 Q37728656-C659F8D5-F9B5-43ED-9014-BB43B90F8101 Q37833132-08292D5E-33DF-4E18-B2A4-474D5FE2B6A3 Q37909424-837F6B4F-8454-45B0-88BB-42B7B2F67B4C Q38207105-6B247935-F50D-4AAB-9C11-A1D16886DB4F Q38271879-74FA3D90-C4DD-430D-A67A-108D689F548D Q39377049-A86AC18C-5DCD-45D1-B486-17C3BA9DA9C5 Q42326772-92D93560-06A8-4DBB-B45B-42FB119B8C3B Q42403489-5F3D375B-61BE-4A45-92BB-BF0BA81D0D59 Q42431181-976238BD-7194-450D-A065-F8DDC20EE536 Q46189367-1A895D5A-1E4D-4FC5-B1A0-CBF9D625F880 Q46624309-6D3733B6-35CF-4174-88BE-80C5D5854332 Q46735662-FE1BFE04-E16B-4012-A810-3C52F3CBBAE7 Q52584367-89EF032D-5313-49CE-BFE2-711E2ED81F74 Q57826568-707DF431-31A5-478A-BFE1-D6999A2CF8FA

P2860

Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

http://www.wikidata.org/entity/Q39705893

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@en

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@nl

type

label

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@en

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@nl

prefLabel

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@en

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@nl

P1433

Q39705893-D31BED42-56C6-4419-8429-07D884D436A5

P1476

Q39705893-5DA8D2A0-0F6E-4085-93A1-079BB7DD79D2

P2093

Q39705893-076CEB54-7E6C-4FB2-A6E4-690795AD6FF5

Q39705893-0A838497-60C9-40AF-BB2C-F113940A0C79

Q39705893-0AF08960-9D1D-4259-B823-FACF66BB24F6

Q39705893-0F59D2B5-D029-4611-97F5-B37E1770A343

Q39705893-23EFE4F1-D40D-40D7-B846-09360EBA7672

Q39705893-5BF75340-652A-4936-B1C5-42AA604A755A

Q39705893-72BDE9D0-E851-4C92-B0F3-EC95213DD663

Q39705893-9C0F2F4E-6DF1-4A83-8F8D-5BD3E33B89F6

Q39705893-BBA15536-60BC-45C2-8E8D-4ED4E945CF83

Q39705893-C927C952-D789-4CC7-8FBE-7FD4316587F0

P2860

Q39705893-03B9879D-5E21-4B16-A318-EFBF82783F38

Q39705893-0E1BB9F4-6CE6-4DD8-B404-442D25C191D2

Q39705893-19C44333-E1EB-4FFA-988E-FA5178DB4F3E

Q39705893-1BCFFA79-5ED6-4C39-8C6A-729D7B240378

Q39705893-1FB86A6C-0C0C-4FBB-822E-DC147B3C9016

Q39705893-22B2B112-43DF-4448-8EEC-3AA20CCDF8C8

Q39705893-2BD6EE93-7154-4BDB-AE25-A08283EADD4E

Q39705893-2E6F6D8E-634B-4833-BE67-674F6F9372DB

Q39705893-32E8C5EA-A07A-4136-8B74-CEEC6316FE4E

Q39705893-37E99BE4-E323-4BC3-95A5-1477CBEC8D67

P2888

Q39705893-AD1F4416-D483-4B87-A1B4-E42E2E228171

P304

Q39705893-F6FE6596-03C8-4915-8196-ADE9C54C6FCA

P31

Q39705893-9FE15E76-10C5-4BB1-ABA8-AFBB86E73E4B

P356

Q39705893-6723DE73-9C02-47EB-8E35-11DE14DBEAAF

P407

Q39705893-FD1FFE90-C60C-4758-A220-2E063D1B9485

P433

Q39705893-A6A86042-897F-440F-9ACE-CA3F10817CFC

P478

Q39705893-10CB1024-E0A3-43F0-BD9B-D8F59683963A

P577

Q39705893-6C7B5119-C5EA-4EBF-8B46-3E172DF1D577

P5875

Q39705893-7F88F5EA-E27F-4062-9354-8ECF55BD1E9A

P6179

Q39705893-A1FA109D-355F-4D0D-8667-9E888976E62C

P698

Q39705893-920D87EA-8FBD-45E8-8F2C-734F3B6EE900

P932

Q39705893-F18D2740-0FC2-450F-83E2-BB7DEBBD51F9

P356

P1433

Journal of Investigative Dermatology

P1476

Imiquimod enhances IFN-gamma p ...... s cell carcinomas of the skin.

@en

P2093

Adam W Calarese

http://www.w3.org/2001/XMLSchema#string

Carl F Schanbacher

http://www.w3.org/2001/XMLSchema#string

Chrysalyne D Schmults

http://www.w3.org/2001/XMLSchema#string

Danielle M Miller

http://www.w3.org/2001/XMLSchema#string

Dirkjan Hijnen

http://www.w3.org/2001/XMLSchema#string

George F Murphy

http://www.w3.org/2001/XMLSchema#string

Ilse G Mollet

http://www.w3.org/2001/XMLSchema#string

Rachael A Clark

http://www.w3.org/2001/XMLSchema#string

Susan J Huang

http://www.w3.org/2001/XMLSchema#string

Thomas S Kupper

http://www.w3.org/2001/XMLSchema#string

P2860

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

Control of regulatory T cell development by the transcription factor Foxp3

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.

The epidemiology of skin cancer.

Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management.

Skin cancers after organ transplantation.

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

P2888

P304

2676-2685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2009.151

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26282450

http://www.w3.org/2001/XMLSchema#string

P6179

1005746052

http://www.w3.org/2001/XMLSchema#string

P698

19516264

http://www.w3.org/2001/XMLSchema#string

P932

2841955

http://www.w3.org/2001/XMLSchema#string